Cimlanod: Difference between revisions
Content deleted Content added
Entranced98 (talk | contribs) Importing Wikidata short description: "Chemical compound" |
nitroxyl etc |
||
| Line 52: | Line 52: | ||
}} |
}} |
||
'''Cimlanod''' (development codes '''CXL-1427''' and '''BMS-986231''') is an experimental drug for the treatment of [[acute decompensated heart failure]]. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by [[Bristol-Myers Squibb]]. It is a [[ |
'''Cimlanod''' (development codes '''CXL-1427''' and '''BMS-986231''') is an experimental drug for the treatment of [[acute decompensated heart failure]]. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by [[Bristol-Myers Squibb]]. It is a [[precursor (chemistry)|precursor]] of [[nitroxyl]].<ref>{{cite web|quote = Alternative Names: BMS-986231; CXL 1427; HNO Donor |url=http://adisinsight.springer.com/drugs/800040055 |title=BMS 986231 | work = AdisInsight | publisher=Springer Nature Switzerland AG |date= |accessdate=2017-05-22}}</ref> |
||
Cimlanod is a [[prodrug]] of CXL-1020.<ref>{{cite web|url=http://adisinsight.springer.com/drugs/800030450 |title=CXL 1020 | work = AdisInsight |publisher=Springer Nature Switzerland AG |date= |accessdate=2017-05-22}}</ref> |
Cimlanod is a [[prodrug]] of CXL-1020.<ref>{{cite web|url=http://adisinsight.springer.com/drugs/800030450 |title=CXL 1020 | work = AdisInsight |publisher=Springer Nature Switzerland AG |date= |accessdate=2017-05-22}}</ref> |
||
A preliminary study showed efficacy in patients with class III and IV heart failure.<ref>{{cite web | title = |
A preliminary study showed efficacy in patients with class III and IV heart failure.<ref>{{cite web | title = Nitroxyl prodrug shows promise in acute heart failure | date = 22 May 2016 | vauthors = Zoler ML | url = http://www.mdedge.com/ecardiologynews/article/109035/heart-failure/nitroxl-prodrug-shows-promise-acute-heart-failure}}</ref> A phase II clinical trial was completed in 2016.<ref>{{ClinicalTrialsGov|NCT02157506|A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure}}</ref> |
||
== References == |
== References == |
||
Latest revision as of 10:49, 22 December 2023
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C5H7NO4S |
| Molar mass | 177.17 g·mol−1 |
| 3D model (JSmol) | |
| |
Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a precursor of nitroxyl.[1]
Cimlanod is a prodrug of CXL-1020.[2]
A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]
References
[edit]- ^ "BMS 986231". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.
Alternative Names: BMS-986231; CXL 1427; HNO Donor
- ^ "CXL 1020". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.
- ^ Zoler ML (22 May 2016). "Nitroxyl prodrug shows promise in acute heart failure".
- ^ Clinical trial number NCT02157506 for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" at ClinicalTrials.gov
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |